Target intelligence / Profile preview

Leucine-rich repeat protein SHOC-2–Muscle RAS oncogene homolog–Protein phosphatase 1 catalytic subunit holophosphatase complex (SMP complex) (SMP complex)

Target
SMP complex
Molecular classification
Enzyme, Protein complex, Phosphatase, Scaffolding protein
01

Overview

The SHOC2-MRAS-PP1C (SMP) holophosphatase complex is a heterotrimeric protein assembly that acts as a key regulator of the RAS-MAPK signaling pathway [1, 13]. It is composed of the leucine-rich repeat (LRR) scaffolding protein SHOC2, the small GTPase MRAS, and the catalytic subunit of protein phosphatase 1 (PP1C) [2, 11]. The complex's primary biological function is to dephosphorylate the inhibitory conserved region 2 (CR2) phosphoserine site on RAF kinases (e.g., S259 in CRAF, S365 in BRAF), a step essential for releasing RAF from its autoinhibited state and allowing it to dimerize and activate the downstream MAPK cascade [5, 15]. Mutations in the components of the SMP complex are associated with RASopathies, such as Noonan syndrome, and the complex is a major driver of resistance to MEK inhibitors in RAS-mutant cancers [11, 17]. Consequently, the SMP complex has emerged as a high-priority therapeutic target, with drug discovery efforts focusing on small-molecule inhibitors and degraders that disrupt its assembly to block oncogenic signaling [8, 16].

Other names
SHOC2-MRAS-PP1C ternary complexSHOC2-MRAS-PP1C complexMRAS-SHOC2-PP1C complexSHOC2-MRAS-PP1C holophosphataseSMP complex
02

Mechanism of action

Inhibition of the SHOC2-MRAS-PP1C complex assembly or protein degradation to prevent the dephosphorylation of RAF kinases, thereby blocking the reactivation of the MAPK signaling pathway [8, 13].

03

Biological functions

Signal transductionRAF activationMAPK pathway regulationProtein dephosphorylationCell proliferationCell survival
04

Disease associations

CancerNoonan syndromeRASopathyLung cancerPancreatic cancer
05

Safety considerations

Potential for systemic toxicity due to broad inhibition of the MAPK pathwayChallenges in targeting the smooth protein-protein interfaces of the SHOC2 scaffoldRisk of adaptive resistance mechanisms
06

Interacting drugs

SHOC2 inhibitors

1 more in the full profile.

07

Biomarkers

KRAS mutationNRAS mutationHRAS mutationSHOC2 mutationMRAS mutationPP1C mutationMEK inhibitor resistance

Beyond the preview

Go deeper on Leucine-rich repeat protein SHOC-2–Muscle RAS oncogene homolog–Protein phosphatase 1 catalytic subunit holophosphatase complex (SMP complex) (SMP complex).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Leucine-rich repeat protein SHOC-2–Muscle RAS oncogene homolog–Protein phosphatase 1 catalytic subunit holophosphatase complex (SMP complex) (SMP complex).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call